Asset Details
Do you wish to reserve the book?
RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes
Do you wish to request the book?
RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes
2019
Overview
Development of chemoresistance remains a major challenge in treating esophageal squamous cell carcinoma (ESCC) patients despite treatment advances. However, the role of RAC1 in chemoresistance of ESCC and the underlying mechanisms remain largely unknown. In this study, we found that higher levels of RAC1 expression were associated with poorer prognosis in ESCC patients. Enhanced RAC1 expression increased cell proliferation, migration, and chemoresistance in vitro. Combination therapy using RAC1 inhibitor EHop‐016 and cisplatin significantly promoted cell viability inhibition, G2/M phase cycle arrest, and apoptosis when compared to each monotherapy. Mechanistically, glycolysis was significantly downregulated in the RAC1 inhibitor monotherapy group and the combination group via inhibiting AKT/FOXO3a signaling when compared to the control group. Moreover, the silencing of RAC1 inhibited AKT/FOXO3a signaling and cell glycolysis while the upregulation of RAC1 produced an opposite effect. In murine xenograft models, the tumor volume and the expression of glycolytic enzymes were significantly reduced in combination therapy when compared to each monotherapy group. Overall, our study demonstrates that targeting RAC1 with an inhibitor overcomes cisplatin resistance in ESCC by suppressing glycolytic enzymes, which provides a promising strategy for treatment of ESCC in clinical practice.
Glycolysis is essential for chemoresistance, anti‐apoptotic signaling, proliferation and migration of cancer cells. Our study reveals the role of RAC1 in regulating glycolytic enzymes. At the molecular level, RAC1 inhibitor suppresses GEF–RAC1 interaction to decrease AKT phosphorylation, which inhibits phosphorylation of FOXO3a and S6, and subsequently downregulates glycolytic enzymes such as PKM, LDHA, and HK1.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Animals
/ Cancer
/ Enzymes
/ Esophageal Neoplasms - drug therapy
/ Esophageal Neoplasms - genetics
/ Esophageal Neoplasms - metabolism
/ Esophageal Neoplasms - pathology
/ esophageal squamous cell carcinoma
/ Esophageal Squamous Cell Carcinoma - drug therapy
/ Esophageal Squamous Cell Carcinoma - genetics
/ Esophageal Squamous Cell Carcinoma - metabolism
/ Esophageal Squamous Cell Carcinoma - pathology
/ Female
/ Gene Expression Regulation, Neoplastic - drug effects
/ Humans
/ Kinases
/ Male
/ Mice
/ Neoplasm Proteins - biosynthesis
/ Neoplasm Proteins - genetics
/ Patients
/ RAC1
/ rac1 GTP-Binding Protein - biosynthesis
/ rac1 GTP-Binding Protein - genetics
/ Surgery
